<DOC>
	<DOCNO>NCT00062478</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ofKarenitecin ( BNP1350 ) treatment adult brain tumor .</brief_summary>
	<brief_title>Study Karenitecin ( BNP1350 ) Patients With Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed diagnosis newly diagnose glioblastoma multiforme recurrent/progressive glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligodendroglioma . Evidence measurable recurrent residual primary CNS neoplasm . An interval least 3 week prior surgical resection 6 week prior radiotherapy chemotherapy , enrollment protocol unless unequivocal evidence tumor progression surgery , radiotherapy , chemotherapy . Hematocrit &gt; 29 % , ANC &gt; 1,500 , platelet &gt; 125,000 Serum creatinine &lt; 1.5 mg/dl , BUN &lt; 25 mg/dl , serum SGOT bilirubin &lt; 1.5 time upper limit normal Negative pregnancy test female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>